Details of the Drug Combination

General Information of Drug Combination (ID: DC0IXSC)

Drug Combination Name
Gemifloxacin Azithromycin
Indication
Disease Entry Status REF
Gonorrhoea Phase 1 [1]
Component Drugs Gemifloxacin   DMHT34O Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gemifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Pneumonia caused by chlamydia N.A. Investigative [3]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [3]
Gemifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [7]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [7]
------------------------------------------------------------------------------------
Gemifloxacin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [4]
Bronchitis CA20 Approved [5]
Chancroid N.A. Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Pneumonia caused by chlamydia N.A. Investigative [4]

References

1 ClinicalTrials.gov (NCT00926796) Efficacy of Combination Therapies for Gonorrhea Treatment
2 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
3 Gemifloxacin FDA Label
4 Azithromycin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
6 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.